Genmab — September 2020

[E_L]

Genmab

annual report p 26 -3,000-4,000 approximate number of new cases diagnosed annually, making AL amyloidosis the most common type of amyloidosis in the U.S - An estimated 16,000 people in the United States suffer from amyloidosis. - 12-15% of multiple myeloma patients develop light chain (AL) amyloidosis.

[E_L]

The problem with amyloidosis is that it is often not recognised immediatley as amyloidosis ; it often comes through other doctors after hearth or renal failure if i understand correctly

[E_L]

i am sure an awareness campaign will be part of the JNJ marketing strategy . There are probably more -unidentified- patients with amyloidosis

[E_L]

Building on BCMA-Directed Therapies in Multiple Myeloma https://www.onclive.com/view/building-on-bcma-directed-therapies-in-multiple-myeloma

[Sukkeralf]

Ocrevus

[Sukkeralf]

https://www.firstwordpharma.com/node/1756560?tsid=1

[Legolas23]

Nice one

[E_L]

Trispecific antibodies take to the clinic -mentions the Sanofi CD3xCD28xCD38 - https://www.nature.com/articles/d41573-020-00164-3

[Sukkeralf]

Paul Parren, CEO of the γδ T cell-engaging bispecific company Lava Therapeutics, is watching this space. “I like bispecifics a lot, and I also like trispecifics a lot,” he says

[Sukkeralf]

Old Genmab guy

[E_L]

yes, and his name still regularly
shows up in publications together with Genmab researchers

[Sukkeralf]

Jep - if Lave Therapeutics goes to market I think I would throw some money after PP

[E_L]

traitor

[E_L]

Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis https://www.novartis.com/news/media-releases/novartis-presents-data-actrims-ectrims-kesimpta-ofatumumab-newly-diagnosed-treatment-naive-adults-relapsing-multiple-sclerosis

[Klarussen]

Genmab begynder at vise svaghedstegn

Kommentarerne til C25-aktierne er primært baseret på teknisk analyse med en tidshorisont på 2-3 uger og ikke dybdegående fundamentalanalyser. Købs- og salgsanbefalingerne er kun vejledende. A. P. Møller – Mærsk A – Hold Aktuel kurs: 8875,00 A. P. Møller – Mærsk A følger stort set selskabets B-aktie, og giver derfor ikke anledning til en selvstændig […]

Økonomisk Ugebrev (ugebrev.dk)

[Klarussen]

Aktieugebrevet: Genmab begynder at vise svaghedstegn

[Helge_LarsenPI-redaktør]

Det er blot en kortsigtet teknisk analyse: https://www.proinvestor.com/investornyt/666637/genmab-begynder-at-vise-svaghedstegn

[Helge_LarsenPI-redaktør]

Enhver har kunnet se denne udvikling i den seneste tid.

[Helge_LarsenPI-redaktør]

Vor
egen tekniske analyse er her: https://www.proinvestor.com/boards/86703/Teknisk-analyse-af-Genmab

[Helge_LarsenPI-redaktør]

God morgen.